Please try another search
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Vaclav Vetvicka | - | - | Member of Scientific Advisory Board |
Bryan Gray | - | 2021 | Independent Non-Executive Director |
Michael Woodward | - | - | Member of Scientific Advisory Board |
Jack Theseus Lowenstein | 67 | 2021 | Independent Non-Executive Chair |
Tony Charara | - | 2012 | Co-Founder & Executive Director |
Thomas E. Serena | - | - | Member of Scientific Advisory Board |
Graham Edmund Kelly | 78 | - | Chief Scientific Advisor |
Mitchel P. Goldman | - | - | Member of Scientific Advisory Board |
Michael Silberberg | - | 2023 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review